Presse Medicale最新文献

筛选
英文 中文
All you need to know about VIPoma: Review on the latest studies 关于 VIPoma 的所有知识:最新研究综述。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-16 DOI: 10.1016/j.lpm.2023.104222
Emija Nikola Karele
{"title":"All you need to know about VIPoma: Review on the latest studies","authors":"Emija Nikola Karele","doi":"10.1016/j.lpm.2023.104222","DOIUrl":"10.1016/j.lpm.2023.104222","url":null,"abstract":"<div><p><span><span>Vasoactive intestinal peptide<span> secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor<span> that is characterized by watery diarrhea, hypokalemia<span> and achlorhydria<span> due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, </span></span></span></span></span>electrolyte balance<span> correction, pharmacological treatment with somatostatin analogs, surgical resection and chemotherapy. This review aims to provide an insight into the latest research on </span></span>VIPoma<span> epidemiology<span>, pathophysiology, diagnostics and treatment.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 2","pages":"Article 104222"},"PeriodicalIF":2.7,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
XBB and BQ.1, the two Omicron cousins dominating globally: Is it the time we should think again? XBB 和 BQ.1,这两个 Omicron 表兄弟在全球范围内占据主导地位:现在是我们重新思考的时候了吗?
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-15 DOI: 10.1016/j.lpm.2023.104220
Rubai Ahmed, Sovan Samanta, Jhimli Banerjee, Sandeep Kumar Dash
{"title":"XBB and BQ.1, the two Omicron cousins dominating globally: Is it the time we should think again?","authors":"Rubai Ahmed,&nbsp;Sovan Samanta,&nbsp;Jhimli Banerjee,&nbsp;Sandeep Kumar Dash","doi":"10.1016/j.lpm.2023.104220","DOIUrl":"10.1016/j.lpm.2023.104220","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104220"},"PeriodicalIF":2.7,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic heart failure with reduced EF: A decade of major pharmacological innovations EF值降低的慢性心力衰竭:十年来的重大药物创新。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-08 DOI: 10.1016/j.lpm.2023.104219
Jean-Noël Trochu
{"title":"Chronic heart failure with reduced EF: A decade of major pharmacological innovations","authors":"Jean-Noël Trochu","doi":"10.1016/j.lpm.2023.104219","DOIUrl":"10.1016/j.lpm.2023.104219","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Because of its severity, prevalence, and medical economic<span> importance, heart failure is a chronic disease that is the subject of intense medical research<span>. The aim of this article was to review the therapeutic innovations of the last decade that have been incorporated into the latest international recommendations for the treatment of heart failure.</span></span></p></div><div><h3>Method</h3><p>Review of literature and current guidelines.</p></div><div><h3>Conclusion</h3><p>The results of the clinical trials<span> reviewed here represent major advances that will have a significant impact on quality of life<span>, survival, rehospitalisation and, for certain treatments, a beneficial joint effect on commonly associated comorbidities such as diabetes and chronic renal failure.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104219"},"PeriodicalIF":2.7,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Main nose-throat-ears, and ophthalmic features in sickle cell disease children 镰状细胞病患儿鼻、喉、耳、眼的主要特征。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-01 DOI: 10.1016/j.lpm.2023.104210
Léon Tshilolo , Joseph Kelekele
{"title":"Main nose-throat-ears, and ophthalmic features in sickle cell disease children","authors":"Léon Tshilolo ,&nbsp;Joseph Kelekele","doi":"10.1016/j.lpm.2023.104210","DOIUrl":"10.1016/j.lpm.2023.104210","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104210"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene-addition/editing therapy in sickle cell disease 镰状细胞病的基因添加/编辑治疗。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-01 DOI: 10.1016/j.lpm.2023.104214
Galia Pollock , Olivier Negre , Jean-Antoine Ribeil
{"title":"Gene-addition/editing therapy in sickle cell disease","authors":"Galia Pollock ,&nbsp;Olivier Negre ,&nbsp;Jean-Antoine Ribeil","doi":"10.1016/j.lpm.2023.104214","DOIUrl":"10.1016/j.lpm.2023.104214","url":null,"abstract":"<div><p><span>Gene therapy is an innovative strategy that offers potential cure for patients with sickle cell disease, and no appropriate donor for transplant consideration. While we await long term data from these </span>clinical trials<span>, we remain optimistic that gene therapy will become a standard of care for curative treatment in sickle cell disease. As gene therapy becomes a standard of treatment in sickle cell disease, we must also acknowledge the potential for financial burden to patients. We also must acknowledge the prevalence of sickle cell disease in low-resource settings. Hopefully, as we learn more about gene therapy, we can assess ways to overcome the financial toxicity that comes with this therapy.</span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104214"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138434920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The liver in sickle cell disease 镰状细胞病的肝脏。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-12-01 DOI: 10.1016/j.lpm.2023.104212
Christophe Duvoux , Lorraine Blaise , Jean-Jacques Matimbo , Francky Mubenga , Norbert Ngongang , Monika Hurtova , Alexis Laurent , Jérémy Augustin , Julien Calderaro , Edouard Reizine , Alain Luciani , Anoosha Habibi , Dora Bachir , Geoffroy Vole , Justine Gellen-Dautremer , Vincent Leroy , Eric Levesque , Pablo Bartolucci
{"title":"The liver in sickle cell disease","authors":"Christophe Duvoux ,&nbsp;Lorraine Blaise ,&nbsp;Jean-Jacques Matimbo ,&nbsp;Francky Mubenga ,&nbsp;Norbert Ngongang ,&nbsp;Monika Hurtova ,&nbsp;Alexis Laurent ,&nbsp;Jérémy Augustin ,&nbsp;Julien Calderaro ,&nbsp;Edouard Reizine ,&nbsp;Alain Luciani ,&nbsp;Anoosha Habibi ,&nbsp;Dora Bachir ,&nbsp;Geoffroy Vole ,&nbsp;Justine Gellen-Dautremer ,&nbsp;Vincent Leroy ,&nbsp;Eric Levesque ,&nbsp;Pablo Bartolucci","doi":"10.1016/j.lpm.2023.104212","DOIUrl":"10.1016/j.lpm.2023.104212","url":null,"abstract":"<div><p>Liver involvement in SCD<span><span><span> patients is frequent but often misdiagnosed or underestimated, except in case of advanced liver diseases. Because of so far poorly recognized forms of chronic SCD-related vascular injury<span> that can silently evolved towards end stages or facilitate ACLF, any persisting </span></span>liver function tests<span> abnormalities should be carefully investigated, following the above proposed algorithm. Work up and management must be considered multidisciplinary in relationship with a Hepatologist. Early SCD hepatopathy should prompt revision of SCD management to prevent further liver injury and decompensation, discussing transfusion exchanges<span> and hydro urea when not yet initiated, and control for any cofactor of liver injury. The role of HSCT in early SCD hepatopathies also deserves evaluation. In advanced SCD hepatopathies, </span></span></span>liver transplantation<span>, which has been rarely performed so far, is the only therapeutic option associated with improved survival. It should definitely be discussed- either electively in case of decompensation in SCD cirrhosis<span> or jaundice/recurrent cholangitis<span> in cholestatic diseases, with excellent outcome, - or emergently in case of ALF or ACLF with more mitigate results.</span></span></span></span></p><p>To improve knowledge and management of SCD liver diseases, creation of national and international registries, as well as longitudinal observational cohorts are encouraged.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104212"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Presentation of polymyalgia rheumatica and large joint polyarthritis in the spectrum of hyper-IgG4-related disease: A case report and literature review 高igg4相关疾病谱系中风湿性多肌痛和大关节多关节炎的表现:一例报告和文献复习
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-11-17 DOI: 10.1016/j.lpm.2023.104206
Remi Roeland , Marine Trenec , Samuel Deshayes , Hubert de Boysson , Kevin Prigent , Achille Aouba
{"title":"Presentation of polymyalgia rheumatica and large joint polyarthritis in the spectrum of hyper-IgG4-related disease: A case report and literature review","authors":"Remi Roeland ,&nbsp;Marine Trenec ,&nbsp;Samuel Deshayes ,&nbsp;Hubert de Boysson ,&nbsp;Kevin Prigent ,&nbsp;Achille Aouba","doi":"10.1016/j.lpm.2023.104206","DOIUrl":"10.1016/j.lpm.2023.104206","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104206"},"PeriodicalIF":2.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ongoing challenge of RBC alloimmunization in the management of patients with sickle cell disease 红细胞同种异体免疫在镰状细胞病患者治疗中的挑战日益增加。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-11-17 DOI: 10.1016/j.lpm.2023.104211
Daniel Y. Chang, Zakary Wankier, Connie M. Arthur, Sean R. Stowell
{"title":"The ongoing challenge of RBC alloimmunization in the management of patients with sickle cell disease","authors":"Daniel Y. Chang,&nbsp;Zakary Wankier,&nbsp;Connie M. Arthur,&nbsp;Sean R. Stowell","doi":"10.1016/j.lpm.2023.104211","DOIUrl":"10.1016/j.lpm.2023.104211","url":null,"abstract":"<div><p><span><span><span>RBC transfusion<span> remains a cornerstone in the treatment of </span></span>sickle cell disease (SCD). However, as with many interventions, transfusion of </span>RBCs<span><span> is not without risk. Allogeneic RBC exposure can result in the development of alloantibodies, which can make it difficult to find compatible RBCs for future transfusion and increases the likelihood of life-threatening complications. The development of RBC alloantibodies occurs when a patient's immune system produces alloantibodies against foreign </span>alloantigens<span> present on RBCs. Despite its longstanding recognition, RBC alloimmunization has increasingly become a challenge when caring for patients with SCD. The growing prominence of alloimmunization can be attributed to several factors, including expanded indications for transfusions, increased lifespan of patients with SCD, and inadequate approaches to prevent alloimmunization. Recognizing these challenges, recent observational studies and preclinical models have begun to elucidate the immune pathways that underpin RBC alloimmunization. These emerging data hold promise in paving the way for innovative prevention strategies, with the goal of increasing the safety and efficacy of RBC transfusion </span></span></span>in patients with SCD who are most vulnerable to alloimmunization.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104211"},"PeriodicalIF":2.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening for cognitive impairment in adults with sickle cell disease: A systematic review and meta-analysis 成人镰状细胞病的认知障碍筛查:系统回顾和荟萃分析
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-11-17 DOI: 10.1016/j.lpm.2023.104207
Maryline Couette , Justine Roy , Damien Oudin Doglioni , Olena Bereznyakova , Christian Stapf , Gregory Jacquin , Valérie Fraïle , Philippe Desmarais , Sara-Maude Desforges , Lahoud Touma , Bénédicte Nauche , Pablo Bartolucci , Kevin H.M. Kuo , Stéphanie Forté
{"title":"Screening for cognitive impairment in adults with sickle cell disease: A systematic review and meta-analysis","authors":"Maryline Couette ,&nbsp;Justine Roy ,&nbsp;Damien Oudin Doglioni ,&nbsp;Olena Bereznyakova ,&nbsp;Christian Stapf ,&nbsp;Gregory Jacquin ,&nbsp;Valérie Fraïle ,&nbsp;Philippe Desmarais ,&nbsp;Sara-Maude Desforges ,&nbsp;Lahoud Touma ,&nbsp;Bénédicte Nauche ,&nbsp;Pablo Bartolucci ,&nbsp;Kevin H.M. Kuo ,&nbsp;Stéphanie Forté","doi":"10.1016/j.lpm.2023.104207","DOIUrl":"10.1016/j.lpm.2023.104207","url":null,"abstract":"<div><p><span>Neurovascular disease such as symptomatic stroke, silent brain infarcts<span><span> and vascular cognitive impairment are common complications of </span>sickle cell disease (SCD) that can have devastating consequences on </span></span>quality of life<span>, employment, and social functioning.  Early recognition of neurovascular disease is a prerequisite for the timely optimization of medical care and to connect patients to adaptive resources. While cognitive impairment has been well described in children, currently available data are limited in adults. As a result, guidance on the optimal cognitive screening strategies in adults is scarce. We conducted a systematic review<span><span> to identify the different screening tools that have been evaluated in SCD. A meta-analysis was performed to estimate the prevalence of suspected cognitive impairment in this population. In this qualitative synthesis, we present 8 studies that evaluated 6 different screening tools. Patient characteristics that impacted on cognitive screening performance included age, education level, and a prior history of stroke. We report a pooled prevalence of 38% [14–62%] of suspected cognitive impairment. We discuss the relative benefits and limitations of the different screening tools to help clinicians select an adapted approach tailored to their specific patients’ needs. Further studies are needed to establish and validate cognitive screening strategies </span>in patients with diverse cultural and educational backgrounds.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104207"},"PeriodicalIF":2.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary hypertension in sickle cell disease 镰状细胞病的肺动脉高压。
IF 2.7 3区 医学
Presse Medicale Pub Date : 2023-11-14 DOI: 10.1016/j.lpm.2023.104209
Salma Al Kahf , Anne Roche , Audrey Baron , Christelle Chantalat-Auger , Laurent Savale
{"title":"Pulmonary hypertension in sickle cell disease","authors":"Salma Al Kahf ,&nbsp;Anne Roche ,&nbsp;Audrey Baron ,&nbsp;Christelle Chantalat-Auger ,&nbsp;Laurent Savale","doi":"10.1016/j.lpm.2023.104209","DOIUrl":"10.1016/j.lpm.2023.104209","url":null,"abstract":"<div><p><span>Sickle cell disease<span><span> (SCD) is a complex genetic disorder that has long challenged both patients and healthcare professionals. One of its chronic and debilitating complications is pulmonary hypertension (PH). SCD-associated PH is often post-capillary, secondary to left heart disease. It can also sometimes be pre-capillary with multiple and often interrelated mechanisms including obstructive remodeling of the pulmonary vascular bed secondary to hemolysis, endothelial dysfunction<span>, thrombosis, hypoxia, or associated risk factors like </span></span>portal hypertension<span>. Screening symptomatic patients with echocardiographic signs of PH is crucial to determine those who should undergo right heart catheterization<span>, the cornerstone exam to diagnose and categorize patients with PH. The workup following the diagnosis relies on identifying the cause of PH to personalize treatment. Ongoing efforts are made to treat this complex condition, starting with treating the underlying disease with </span></span></span></span>hydroxyurea<span> or chronic blood exchange transfusion<span>. Robust data on the efficacy of PAH-specific therapies are lacking in this specific population. Initiation of such therapies must be made by an expert center after a case-by-case assessment of the benefit-risk ratio according to the phenotype and the mechanisms involved in the development of PH. Efforts are also poured into studying the interventional and medical therapies used on chronic thromboembolic PH for patients presenting with a thrombotic form. The management of those patients requires a multidisciplinary approach, with conjoint efforts from PH and SCD specialists.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104209"},"PeriodicalIF":2.7,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信